跳至主要内容
临床试验/NCT04542629
NCT04542629Unknown4 期

Comparative Study of Dietary and Immunological Management of Refractory Epilepsy in Children Attending Assiut Pediatric University Hospital

Assiut University0 个研究点目标入组 140 人开始时间: 2020年10月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
入组人数
140
主要终点
a-seizure frequency b-antiepileptic drugs c-compliance to treatment d-number of hospital admission

研究概览

简要总结

  1. Comparison of the efficacy of Rituximab and ketogenic diet in controlling refractory seizures versus the traditional lines as corticosteroid and trace elements.
  2. Improving the management of children with refractory seizures

详细描述

  1. Definition of refractory epilepsy

A task force of the International League Against Epilepsy proposed that drug-resistant epilepsy be defined as failure of adequate trials of two tolerated and appropriately chosen and used antiseizure drug schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom (1)

. This requires application of the intervention at adequate strength/dosage for a sufficient length of time (2)..Terms refractory" intractable", drug-resistant" pharmaco-resistant" have been used interchangeably in several documented literature in different time periods (3). The first antiseizure drug fails in 20 to 40 percent of children with epilepsy; lack of efficacy and side effects contribute to treatment failure (4)

Epidemiology About 10-20 % children with epilepsy develop drug refractory epilepsy (5).In a systematic review of 35 observational studies that included over 13,000 patients with epilepsy and 3900 patients with drug resistant epilepsy( DRE), the pooled prevalence of (DRE) was 30 percent, and the pooled incidence proportion was 15 percent (6).

Risk factors

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
1 Month 至 17 Years(Child)
性别
All
接受健康志愿者

入选标准

  • 1-Age 1 month up to 17 years 2-Both male and female 3-Epileptic patient on two tolerated and appropriately chosen and used antiepilptic drugs with no response

排除标准

  • 1-Neonate 2-Epieptic patient on monotherapy 3-Conditions mimic epilepsy 4-Pseudo refractioness 5-Absolute contraindications for the use of diet therapy include carnitine deficiency (primary), carnitine palmitoyltransferase (CPT) I OR II deficiency, carnitine translocase deficiency, β-oxidation defects, pyruvate carboxylase deficiency, and porphyria 6-Contraindication for Rituximab:
  • Hypersensitivity to any component, murine proteins. b. Heart failure c. Active infection

研究组 & 干预措施

RITUXIMAB

Experimental

rituximab INTRAVENOUS 750MG/m2 every 2 weeks for 2 doses

干预措施: RiTUXimab Injection [Rituxan] (Drug)

KETOGENIC DIET

Active Comparator

The common element of these different approaches is variable reduction in the amount of carbohydrate with appropriate increase in fat.

Diets that produce a state of ketosis are referred to as ''ketogenic"

干预措施: RiTUXimab Injection [Rituxan] (Drug)

TRACE ELEMENTS

Active Comparator

. Essential trace elements that include zinc, copper, magnesium, and selenium

干预措施: RiTUXimab Injection [Rituxan] (Drug)

CORTICOSTEROID

Active Comparator

corticosteroid pulse therapy 30 mg /kg /day for 5 days monthly for 6 month

干预措施: RiTUXimab Injection [Rituxan] (Drug)

结局指标

主要结局

a-seizure frequency b-antiepileptic drugs c-compliance to treatment d-number of hospital admission

时间窗: 1 YEAR

number of attacks of fits during monitoring

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Nancy Alaa

Principle investigator

Assiut University

相似试验